MedTrace Logo

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

NCT02181517 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-05-17

Study results available
· View outcomes & findings →

Summary

This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.

Conditions

  • Macular Degeneration

Interventions

DRUG

abicipar pegol

Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.

DRUG

ranibizumab

Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.

OTHER

sham procedure

Sham procedure to the study eye at weeks 12 and 16.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02181517 on ClinicalTrials.gov